Study identifier:D7460C00001
ClinicalTrials.gov identifier:NCT04076540
EudraCT identifier:N/A
CTIS identifier:N/A
A phase I randomized, double-blind placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of AZD4041 following single ascending dose administration to Healthy Volunteers
Smoking cessation
Phase 1
Yes
AZD4041, Placebo
All
48
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Nov 2021 by AstraZeneca
AstraZeneca
National Institutes of Health (NIH), Eolas Therapeutics INC.
This is a Phase I, first-in-human (FIH), single-center, randomized, double-blind, placebo controlled, single ascending dose, sequential group study in healthy vasectomized male and female subjects of non-childbearing potential, aged 18 to 65 years.
No locations available
Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy.
Show more publicationsArms | Assigned Interventions |
---|---|
Experimental: AZD4041 | Drug: AZD4041 Administration by Oral syringe |
Placebo Comparator: Placebo | Drug: Placebo Administration by Oral syringe |